Back to Authors

Silva, Fernando Eduardo Calais Da

Mayo Clinic

Unidade Local de Saúde de São José

Citations 3

Association of germline variation with androgen ablation (AA) failure in advanced hormone-sensitive prostate cancer (HSPC).
Zhang, Ben Yiming, Riska, Shaun M., Lee, Adam M , Quevedo, Fernando , Costello, Brian A. , Pitot, Henry C., Monteiro, Cátia, Nogueira, Augusto, Maurício, Joaquina, Fraga, Avelino , Silva, Fernando Eduardo Calais Da, Kochuparambil, Samith T. , Mahoney, Douglas W. , McDonnell, Shannon K. , Lee, Adam M. , Ribeiro, Ricardo , Medeiros, Rui , Cerhan, James R. , Kohli, Manish

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16117-e16117

10.1200/jco.2015.33.15_suppl.e16117 Get It

Variation in TRMT11 gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (CRPC) patients.
Zhang, Ben Yiming, Riska, Shaun M., Monteiro, Cátia, Costello, Brian A. , Dronca, Roxana , Pitot, Henry C., Moynihan, Timothy J. , Maurício, Joaquina, Fraga, Avelino , Silva, Fernando Eduardo Calais Da, Mahoney, Douglas W. , Ribeiro, Ricardo , Medeiros, Rui , Cerhan, James R. , Quevedo, Fernando , Kochuparambil, Samith T. , Kohli, Manish

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 255-255

10.1200/jco.2015.33.7_suppl.255 Get It

255 Background: In a prior study, we found that 8 single nucleotide polymorphisms (SNPs) from 4 candidate hormone-related genes (JAK2, TRMT11, NKX3-1 and HSD17B12) were associated with overall survival (OS) in CRPC stage in a North American cohort of 519 subjects. We attempt to replicate these findings in an independent cohort of Portuguese patients. Methods: A hundred and forty CRPC stage patients in the new cohort were genotyped fort he candidate SNPs. The primary endpoint was overall survival (OS), defined as time from development of CRPC to death. For SNP level results we estimated hazard ratios (HR) and 95% confidence intervals (CI) under the dominant allele model using Cox regression and adjusted for age and Gleason score (GS). Results: The median age of the Portuguese cohort was 69 years (range 53-84). The GS distribution was 48% subjects with GS≥8; 35% with GS=7 and 17% with GS<7. Median time from castration resistance to death for the cohort was 2.2 years (IQ range: 0.8-3.4, 93 deaths). One of the 3 SNPs (rs2295005; C>G; MAF = 0.16) in the TRMT11gene was associated with OS after adjustment for age and GS: (dominant model p=0.05, HR=0.56; 95 CI=0.31-1.00). No other SNP was observed to have statistical significance with OS (Table 1). Conclusions: Variation in the TRMT11 gene is significantly associated with overall survival in patients with CRPC and warrants further validation as a potential prognostic biomarker. [Table: see text]
Association of germline variation with androgen ablation (AA) failure in advanced hormone-sensitive prostate cancer (HSPC).
Zhang, Ben Yiming, Riska, Shaun M., Lee, Adam M , Costello, Brian A. , Pitot, Henry C., Monteiro, Cátia, Nogueira, Augusto, Maurício, Joaquina, Fraga, Avelino , Silva, Fernando Eduardo Calais Da, Kochuparambil, Samith T. , Mahoney, Douglas W. , McDonnell, Shannon K. , Lee, Adam M. , Quevedo, Fernando , Ribeiro, Ricardo , Medeiros, Rui , Cerhan, James R. , Kohli, Manish

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 209-209

10.1200/jco.2015.33.7_suppl.209 Get It

209 Background: Predictive markers of response to AA are not known. In a prior study, we found that 8 single nucleotide polymorphisms (SNPs) from 4 candidate hormone-related genes (JAK2, TRMT11, NKX3-1 and HSD17B12) were associated with response to AA in HSPC in a North American cohort of 519 subjects. We attempt to replicate these findings in a cohort of Portuguese patients. Methods: The Portuguese cohort consisted of 308 HSPC patients, and the primary endpoint was time to AA failure, defined as time from initiating continuous AA to two serial PSA increases over the nadir, initiation of chemotherapy for progressive disease, or clinical or imaging based progression, whichever came first. For each SNP, we calculated hazard ratios (HRs) and 95% confidence intervals (CI) for time to AA failure using a recessive model with adjustment for Gleason score (GS). Results: The median age of the Portuguese cohort was 69 years (range 43, 85). The GS distribution was 35% subjects with GS≥8; 35% with GS=7 and 30% with GS<7. Median time to AA failure for the cohort was 1.8 years (IQ range: 0.3, 3.6). Association of each SNP with time to AA failure is shown in the Table. None of the SNPs replicated. However, there was a suggestive inverse association for rs10503733 (NKX3.1) with time to AA failure (P=0.07). Conclusions: While we were not able to replicate our initial findings, there was an unexpected association with rs10503733 (NKX3.1 gene) that may warrant additional clinical validation. [Table: see text]